|
Letter Describes Human Parthenogenetic Stem Cell Company's Distinct Science and Business Model International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human stem cells from unfertilized eggs, has issued a letter to its shareholders. To view the shareholder letter in its entirety, please follow the link to the company's website: www.internationalstemcell.com/shareholderletter.htm. In the letter, International Stem Cell CEO, Ken Aldrich, updates shareholders on the company's continued efforts to increase shareholder value related to its key initiatives, which include: - Providing the company's proprietary cells to leading worldwide academic and scientific research institutions, while retaining the rights to develop and commercialize products that are derived from these joint ventures
- Driving awareness to the potential that human parthenogenetic stem cells have for curing disease while avoiding certain ethical problems that surround the use of embryonic stem cells
- Human parthenogenic stem cell advantages over those of newly discovered induced pluripotent cells
- Rapid revenue growth through its Lifeline Cell Tech subsidiary
- Recent hiring of the Investor Relations Group to build public awareness
About International Stem Cell Corporation International Stem Cell Corporation (ISCO) is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "stem cell bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. The Investor Relations Group
212-825-3210
Investor Relations:
Adam Holdsworth
aholdsworth@investorrelationsgroup.com
or
Erica Ruderman
eruderman@investorrelationsgroup.com
or
Brett Foley
bfoley@investorrelationsgroup.com
or
Media Relations:
Laura Colontrelle
lcolontrelle@investorrelationsgroup.com |
